Verus Pharmaceuticals Inc., a company with no technology platform, no products and no plans for R&D, raised total funding of $98 million in its Series A round. (BioWorld Today)
LONDON - Jonathan Kil, president and CEO of Sound Pharmaceuticals Inc., is looking for a considerable first round of funding - as much as $40 million, although that might be done in tranches, with a first closing for $10 million.
LONDON - Jonathan Kil, president and CEO of Sound Pharmaceuticals Inc., is looking for a considerable first round of funding - as much as $40 million, although that might be done in tranches, with a first closing for $10 million.
